Rapafusyn Research & Development

Rapafusyn is a biotechnology company focused on the discovery and development of a novel class of macrocyclic small molecules known as Rapafusyns. Utilizing its proprietary Rapa-GLUE platform, the company creates molecular glues that leverage the abundant intracellular protein FKBP12 as a chaperone to target previously undruggable proteins. These macrocycles are designed to induce neo-protein-protein interactions, providing a unique mechanism to modulate disease-relevant targets such as KRAS. Based on technology licensed from Johns Hopkins University, Rapafusyn aims to address high-value targets in oncology and other therapeutic areas. The company's approach combines the specificity of biologics with the delivery advantages of small molecules.